? After 20 years, the North Shore CCOP has evolved into a multidisciplinary approach for studying cancer prevention, control and treatment involving physicians from Nassau, Suffolk and Queens Counties in New York. Currently, 81 full-time medical and radiation oncologists plus surgeons, nurse oncologists, social workers and other support staff participate at a variety of locations from physician's offices to medical institutions. The CCOP is part of the NS-LIJ Health System, which has 2 tertiary and 9 other medical institutions in its catchment area to ensure that appropriate populations, including women and minority groups, are accessible to NCI sponsored studies. The North Shore CCOP is the only NCI sponsored clinical oncologic research program on Long Island that is available to its 5+ million-population base. Accrual to the CCOP in the past 5 years has been excellent with a total of 547.3 treatment credits and 325.1 cancer control credits with 1,804 patients enrolled on studies. Cancer incidence in the catchment area is expected to increase by as much as 11.4 percent in the next five years. It is expected that the only issue limiting an increase to a projected 2,800 patients enrolled in studies in the next 5 years is available funding. ? ? The aims for this grant cycle are: (a) improved patient recruitment including increased minority and female enrollment and increased utilization of community practices and outlying institutions through the Nassau Partnership for Healthy Communities program, organization of a community advisory board and expanded use of the Health System's public education programs. (b) improved physician recruitment and performance and increased CCOP participation from specialists other than oncologists, especially in cancer control and prevention trials, by increasing resources to participating physicians to reduce the burden of participating in clinical trials while ensuring data accuracy and timeliness. This will include improving community practitioner access to CCOP protocols via the Health System's telemedicine program and assistance from dedicated outreach nurse coordinators. (c) improved CCOP management including an upgraded data collection and reporting system. Current research bases include: CALGB, NSABP, URCC, UMCC and RTOG. The UMCC Research Base was recently added. Members of the CCOP have been active in the various research bases' activities and have served as members of co-operative group committees, auditors and as principal investigators with main author publications for national studies. We expect that continued support for this program will permit the North Shore CCOP is expand its activities and increase opportunities for oncology patients to receive optimal care in their home environments. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035279-22
Application #
6926026
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-09-15
Project End
2010-05-31
Budget Start
2005-08-21
Budget End
2006-05-31
Support Year
22
Fiscal Year
2005
Total Cost
$352,234
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7

Showing the most recent 10 out of 111 publications